{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:36Z","timestamp":1791650556456,"version":"4.3.4"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-eoi260010-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Some but not all clinical trials have found 0.05% atropine effective for myopia control; however, discontinuation management remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260010-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate a taper vs stop treatment discontinuation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260010-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This randomized clinical trial involved children aged 4 to 12 years originally from the Low-Concentration Atropine for Myopia Progression (LAMP) study who were followed up for 8 years. All children who completed year 5 follow-up and were receiving atropine treatment were randomized into taper and stop groups at a 1:1 ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260010-7\">\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>During the prediscontinuation period (year 6), participants in the taper group received 0.05% atropine for 6 months and then 0.025% atropine for another 6 months, while the stop group received 0.05% atropine eye drops for a full year. During the discontinuation period (years 7 and 8), all participants stopped the treatment and were monitored for 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260010-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Myopia progression in the taper and stop groups over 3 years; proportion of good response to treatment discontinuation, defined as spherical equivalent (SEP) progression \u22120.5 diopter (D) or more in both eyes during the discontinuation period; and associated factors with myopia progression over 3 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260010-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 246 children who completed the year 5 follow-up, 180 children (73.2%) went on to complete 8 years of follow-up. The mean (SD) age was 13.47 (1.63) years; there were 139 male children (56.5%) and 107 female (43.5%). Over 3 years, SEP and axial length (AL) elongation were faster in the stop group than in the taper group: \u20130.78 D vs \u20130.54 D, respectively (difference, \u22120.24 D; 95% CI, \u22120.46 to \u22120.03 D;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.02) and 0.44 mm vs 0.33 mm, respectively (difference, 0.11; 95% CI, 0.03 to 0.19 D;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.01). The proportion of good response to treatment discontinuation in the taper group was greater than in the stop group (65.1% vs 42.6%, respectively;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.003). Younger age and more myopic spherical equivalent\/longer AL at prediscontinuation were associated with faster SEP and AL elongation over 3 years. Notably, the younger the age and the more myopic the spherical equivalent, the greater the estimated mean differences of SEP\/AL elongation between the taper and stop groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260010-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This study found that over 3 years, the participants in the taper group had less myopia progression than the stop group, particularly in children who were younger and had more myopia. However, to our knowledge, the clinical relevance of this approximately 0.25-D difference between treatment groups is not well understood from the current medical literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.0436","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:30:25Z","timestamp":1774539025000},"page":"396","source":"Crossref","is-referenced-by-count":8,"title":["Discontinuation Approach and Follow-Up of Low-Concentration Atropine for Myopia Progression"],"prefix":"10.1001","volume":"144","author":[{"given":"Yuzhou","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu Juan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Zaabaar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene C.","family":"Yim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Hong Kong Eye Hospital, Hong Kong"},{"name":"Department of Ophthalmology, Hong Kong Children\u2019s Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H. K.","family":"Yip","sequence":"additional","affiliation":[{"name":"Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Wai","family":"Kam","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy P. H.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin L.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement C.","family":"Tham","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Hong Kong Eye Hospital, Hong Kong"},{"name":"Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong"},{"name":"Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong"},{"name":"Department of Ophthalmology, Hong Kong Children\u2019s Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Jia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Hong Kong Eye Hospital, Hong Kong"},{"name":"Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong"},{"name":"Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Pui","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Yam","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong"},{"name":"Hong Kong Eye Hospital, Hong Kong"},{"name":"Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong"},{"name":"Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong"},{"name":"Department of Ophthalmology, Hong Kong Children\u2019s Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9827","key":"eoi260010r1","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia.","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"eoi260010r2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050.","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi260010r3","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1136\/bjophthalmol-2021-319307","article-title":"Myopia incidence and lifestyle changes among school children during the COVID-19 pandemic: a population-based prospective study.","volume":"106","author":"Zhang","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"eoi260010r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4080","article-title":"Prevalence of myopia in children before, during, and after COVID-19 restrictions in Hong Kong.","volume":"6","author":"Zhang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"eoi260010r5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis.","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"eoi260010r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2024.100122","article-title":"Low-concentration atropine for controlling myopia onset and progression in East Asia.","volume":"13","author":"Zaabaar","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"6","key":"eoi260010r7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","article-title":"Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial.","volume":"329","author":"Yam","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"eoi260010r8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi260010r9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control.","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"eoi260010r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2025.101410","article-title":"Interventions to reduce incidence and progression of myopia in children and adults.","volume":"109","author":"Yam","year":"2025","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"eoi260010r11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","article-title":"Five-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: phase 4 report.","volume":"131","author":"Zhang","year":"2024","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi260010r12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/bjo-2022-322808","article-title":"Five-year results of atropine 0.01% efficacy in the myopia control in a European population.","volume":"108","author":"Moriche-Carretero","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"eoi260010r13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ajo.2024.12.029","article-title":"Controversies in myopia control treatment: what does it mean for future research?","volume":"272","author":"Lanca","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi260010r14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control.","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi260010r16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.","volume":"157","author":"Chia","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi260010r17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of Low-Concentration Atropine for Myopia Progression (LAMP) study: continued versus washout: phase 3 report.","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi260010r18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: phase 2 report.","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"issue":"22","key":"eoi260010r19","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"eoi260010r20","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1136\/bjo.2009.158428","article-title":"Development of a Chinese version of the National Eye Institute Visual Function Questionnaire (CHI-VFQ-25) as a tool to study patients with eye diseases in Hong Kong.","volume":"93","author":"Chan","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi260010r21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials: a practical guide with flowcharts.","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"eoi260010r22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/303728","article-title":"Generalized estimating equations in longitudinal data analysis: a review and recent developments.","volume":"2014","author":"Wang","year":"2014","journal-title":"Adv Stat"},{"issue":"4","key":"eoi260010r23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: an orientation.","volume":"157","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"7","key":"eoi260010r24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF00181282","article-title":"Effects of atropine treatment on in vitro and in vivo binding of 4-[125I]-dexetimide to central and myocardial muscarinic receptors.","volume":"18","author":"Uno","year":"1991","journal-title":"Eur J Nucl Med"},{"issue":"4596","key":"eoi260010r25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/science.6132446","article-title":"Vasoactive intestinal polypeptide and muscarinic receptors: supersensitivity induced by long-term atropine treatment.","volume":"220","author":"Hedlund","year":"1983","journal-title":"Science"},{"issue":"3","key":"eoi260010r26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia.","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"issue":"2","key":"eoi260010r27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/02713683.2025.2567593","article-title":"Changes in axial length and refraction after gradual versus prompt cessation of atropine 0.01% treatment for myopia management.","volume":"51","author":"Erdinest","year":"2026","journal-title":"Curr Eye Res"},{"issue":"2","key":"eoi260010r28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamaophthalmol.2024.5703","article-title":"Efficacy and safety of different atropine regimens for the treatment of myopia in children: three-year results of the MOSAIC randomized clinical trial.","volume":"143","author":"Loughman","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"eoi260010r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100773","article-title":"Scleral structure and biomechanics.","volume":"74","author":"Boote","year":"2020","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"eoi260010r30","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1167\/iovs.14-14894","article-title":"Human scleral structural stiffness increases more rapidly with age in donors of African descent compared to donors of European descent.","volume":"55","author":"Fazio","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"eoi260010r31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.neuron.2004.08.008","article-title":"Homeostasis of eye growth and the question of myopia.","volume":"43","author":"Wallman","year":"2004","journal-title":"Neuron"},{"issue":"11","key":"eoi260010r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241759","article-title":"Myopia progression varies with age and severity of myopia.","volume":"15","author":"Verkicharla","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"eoi260010r33","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/bjophthalmol-2020-318256","article-title":"Progression of myopia in children and teenagers: a nationwide longitudinal study.","volume":"106","author":"Tricard","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"eoi260010r34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/bjophthalmol-2019-314619","article-title":"Longitudinal changes in axial length in high myopia: a 4-year prospective study.","volume":"104","author":"Lee","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi260010r35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamaophthalmol.2021.5067","article-title":"Incidence and progression of myopia in early adulthood.","volume":"140","author":"Lee","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"eoi260010r36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren.","volume":"27","author":"Wu","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"eoi260010r37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study.","volume":"159","author":"Loh","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"eoi260010r38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia.","volume":"31","author":"Clark","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"eoi260010r39","doi-asserted-by":"publisher","first-page":"01081","DOI":"10.3389\/fphar.2020.01081","article-title":"Analysis of factors that may affect the effect of atropine 0.01% on myopia control.","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"eoi260010r40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.66.12.39","article-title":"IMI-interventions for controlling myopia onset and progression 2025.","volume":"66","author":"Bullimore","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"eoi260010r15","unstructured":"World Health Organization. The impact of myopia and high myopia: report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia. 2015. Accessed February 23, 2026. https:\/\/myopiainstitute.org\/wp-content\/uploads\/2020\/10\/Myopia_report_020517.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2846905\/jamaophthalmology_zhang_2026_oi_260010_1778698678.60183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:53Z","timestamp":1779375653000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2846905"}},"subtitle":["Eight-Year Results of the LAMP Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.0436","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}